GlassScriptPhysician profile
Barbara M Mackie
NPI 1861492852
$10,522.83
in general payments reported to CMS, 2019-2025
27 companies · $1,485 in 2025
The $1,485 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $760 · 2020: $1,367 · 2021: $1,717 · 2022: $1,632 · 2023: $1,733 · 2024: $1,828 · 2025: $1,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,024 · Education: $22.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,023.60 |
| Education | $22.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,828.34 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,349.54 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $1,115.36 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $1,106.24 | 2019-2025 | Xolair |
| Optinose US, INC. | $939.88 | 2019-2025 | |
| Glaxosmithkline, LLC. | $716.11 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Kaleo, INC. | $711.03 | 2019-2024 | Auvi-Q |
| Pfizer INC. | $507.28 | 2019-2025 | |
| Abbvie INC. | $457.46 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $257.37 | 2022-2025 | Takhzyro, Eohilia |
| Incyte Corporation | $196.69 | 2021-2025 | Opzelura |
| Csl Behring | $183.70 | 2019-2025 | Andembry |
| Novartis Pharmaceuticals Corporation | $165.84 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $164.99 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $131.59 | 2023-2024 | Orladeyo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $110.38 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.92 | 2020-2022 | |
| Greer Laboratories, INC. | $92.91 | 2024-2025 | Oralair |
| Leo Pharma INC. | $87.16 | 2022-2023 | Adbry |
| Aimmune Therapeutics, INC. | $67.38 | 2022-2023 | |
| Amgen INC. | $60.45 | 2022-2024 | Tezspire |
| Alk-Abello, INC | $60.22 | 2021-2024 | Timothy, Standardized, Standardized Mite D. Farinae, Pre-Pen |
| Lilly USA, LLC | $38.45 | 2025 | Taltz, Ebglyss |
| Galderma Laboratories, L.P. | $19.48 | 2025 | Nemluvio |
| Genentech, INC. | $17.38 | 2025 | Xolair |
| Biocryst Pharmaceuticals, INC. | $15.12 | 2020 | |
| Phadia US INC. | $14.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Mackie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.